Mashaly Aya H, Anwar Rokiah, Ebrahim Mohamed A, Eissa Laila A, El Shishtawy Mamdouh M
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Email:
Asian Pac J Cancer Prev. 2018 Jun 25;19(6):1503-1508. doi: 10.22034/APJCP.2018.19.6.1503.
Background: Hepatocellular carcinoma (HCC) is a main cause of cancer death all over the world. Treatment and outcome of HCC based on its early diagnosis. This study was conducted to estimate the role of talin-1 and midkine in combination with total antioxidant capacity (TAC) as tumor markers in HCC patients. Methods: Serum levels of talin-1 and midkine were measured in 90 Egyptian subjects including 44 patients with HCC, 31patients with cirrhosis and 15 healthy controls using enzyme-linked immunosorbent assay (ELISA) technique. While a colorimetric method was used for measurement of TAC. Results: Serum talin-1 in HCC patients was significantly lower than that in patients with cirrhosis (P<0.001) and normal control (P<0.001). In addition, increased invasion and metastasis correlated with reduced talin-1 level. Serum midkine in HCC patients was significantly higher compared to cirrhotic patients (P<0.001) and normal control (P<0.001). Midkine at a cut off value of 1683 pg/ml showed a sensitivity of (81.82%) and specificity of (83.87%). While alpha-fetoprotein (AFP) at a cut off value of 200 ng/ml had a sensitivity of (52.27%), while specificity was (96.77%). Midkine was positive in 80.9% of HCC patients with negative AFP. Serum TAC was significantly decreased in HCC patients when compared with control group (P<0.001). Conclusion: Talin-1 may be implicated in the carcinogenesis and metastasis of HCC and can be used as a useful tumor marker for HCC. Midkine may be a potential diagnostic marker for HCC and may be used in addition to AFP to increase the sensitivity of HCC detection.
肝细胞癌（HCC）是全球癌症死亡的主要原因之一。HCC的治疗和预后取决于早期诊断。本研究旨在评估踝蛋白-1（talin-1）、中期因子（midkine）与总抗氧化能力（TAC）联合作为HCC患者肿瘤标志物的作用。方法：采用酶联免疫吸附测定（ELISA）技术，检测90例埃及受试者的血清talin-1和midkine水平，其中包括44例HCC患者、31例肝硬化患者和15例健康对照者。采用比色法测定TAC。结果：HCC患者血清talin-1水平显著低于肝硬化患者（P<0.001）和正常对照者（P<0.001）。此外，侵袭和转移增加与talin-1水平降低相关。HCC患者血清midkine水平显著高于肝硬化患者（P<0.001）和正常对照者（P<0.001）。Midkine截断值为1683 pg/ml时，灵敏度为81.82%，特异性为83.87%。而甲胎蛋白（AFP）截断值为200 ng/ml时，灵敏度为52.27%，特异性为96.77%。AFP阴性的HCC患者中，80.9%的患者midkine呈阳性。与对照组相比，HCC患者血清TAC显著降低（P<0.001）。结论：Talin-1可能参与HCC的发生和转移，可作为HCC有用的肿瘤标志物。Midkine可能是HCC的潜在诊断标志物，可与AFP联合使用以提高HCC检测的灵敏度。
